Objective Accumulating evidence suggests that the use of proton pump inhibitors (PPIs) is associated with spontaneous bacterial peritonitis (SBP) in cirrhotic patients, although the results are inconsistent. We aimed to examine whether PPI use is associated with SBP in Japan, where the administration of PPIs is strictly regulated. Methods In this single-center retrospective study, we reviewed 65 patients with liver cirrhosis who were admitted between January 2008 and January 2013 due to ascites. The administration of any PPI for at least one week prior to admission was regarded as PPI use. Results Eighteen cirrhotic patients with SBP and 47 without SBP were identified. Both the serum bilirubin levels and international normalized ratio (INR) values were significantly elevated in the patients with SBP (p=0.007, 0.002). The model for end-stage liver disease scores (mean±SD) were 16.1±9.9 and 12.5±9.3 in those with and without SBP (p=0.009), respectively. PPIs were used in 16 out 18 in patients with SBP and 27 of 47 patients without SBP (p=0.002). A multivariate analysis identified INR (odds ratio (OR)=15.3, 95% CI 2.96-76.9, p=0.001) and PPI use (OR=6.41, 95% CI=1. 16-35.7, p=0.033) to be independent risk factors for SBP. Conclusion The use of PPIs in cirrhotic patients with ascites is independently associated with SBP in the Japanese clinical setting.
Introduction
Spontaneous bacterial peritonitis (SBP) is the most common infection in patients with liver cirrhosis and can be lifethreatening without prompt recognition and appropriate treatment (1) . The diagnosis of SBP is based on the detection of an elevated polymorphonuclear leukocyte count to more than 250 cells/mm 3 in ascites fluid without an evident intra-abdominal origin of bacterial infection (2) . SBP is caused by bacterial translocation across the intestinal wall to mesenteric lymph nodes, resulting in the bacteremic seeding of ascites (3, 4) . Bacterial overgrowth in the small intestine due to impaired motility of the small intestine frequently occurs in patients with liver cirrhosis, and increased intestinal permeability as well as compromised host defenses predispose such patients to the proliferation of bacteria in ascites fluid (1, 2, 5) .
The administration of gastric acid suppression therapy, with proton pump inhibitors (PPIs) in particular, is widely used in patients with liver cirrhosis for a broad range of indications, from the treatment of heartburn and peptic ulcers to healing following endoscopic treatment of esophageal/ gastric varices (6) . In contrast, it is largely accepted that gastric acid plays an important role in decontaminating the stomach and proximal small intestine. In this regard, gastric acid suppression therapy is a predisposing factor for bacterial overgrowth in the small intestine in patients with cirrhosis, thereby inducing the development of SBP. Indeed, several lines of evidence suggest that the use of PPIs is significantly associated with a greater risk of developing SBP in cirrhotic patients (7) (8) (9) (10) , and recent meta-analyses confirm this association (11, 12) . However, other studies have failed to indicate treatment with PPIs as an independent risk factor for SBP in multivariate analyses (13) (14) (15) . Therefore, it remains controversial whether the administration of PPIs specifically increases the risk of SBP, irrespective of the progression of liver disease, in patients with cirrhosis. In addition, no clinical studies investigating the association between the use of PPIs and the incidence of SBP have been performed in Japan, where the administration of PPIs by physicians is strictly regulated by the national health insurance system and the overuse of PPIs without appropriate indications is theoretically prevented.
In this study, we aimed to retrospectively examine whether treatment with PPIs is associated with the development of SBP among hospitalized patients with liver cirrhosis due to the accumulation of ascites in the clinical setting in Japan.
Materials and Methods

Study design and inclusion criteria
This study was conducted as a single-center retrospective study. We reviewed 65 patients with liver cirrhosis admitted to Teikyo University Hospital between January 2008 and January 2013 due to ascites who underwent diagnostic paracentesis. Patients with active gastrointestinal hemorrhage and intra-abdominal bleeding due to carcinomatosa or rupture of hepatocellular carcinoma within two weeks prior to admission were excluded. Liver cirrhosis was diagnosed clinically based on blood chemistry and imaging studies. Diagnostic paracentesis was performed on admission in all patients with ascites when the procedure could be safely performed, and the diagnosis of SBP was made when the polymorphonuclear leukocyte count in the ascites fluid was greater than 250 cells/mm 3 without an evident intra-abdominal origin of bacterial infection, with or without a positive culture of the ascites fluid (2) . We collected demographic information on admission, including the etiology of cirrhosis and the occurrence of complications in the past or present, such as esophageal/gastric varices, gastrointestinal hemorrhage, hepatic encephalopathy and hepatocellular carcinoma. We also collected information regarding laboratory data on admission, episodes of bacterial infection occurring within one month prior to admission, the use of H2 blocker antagonists, diuretics or antibiotics within one month prior to admission, the model for end-stage liver disease (MELD) score and the Child-Pugh classification for each patient. The results of bacterial cultures of the ascites fluid performed before the commencement of antibiotic therapy were reviewed.
Definition of PPI use
The administration of any PPI for at least one week prior to admission was regarded as PPI use. A single dose of a PPI was not included at PPI use. The duration of PPI use was categorized according to the interval of administration prior to admission: between seven to 90 days, and more than 90 days. Additionally, we reviewed the indication for PPI use in each patient with and without SBP. Therapeutic PPI use was defined as appropriate if the indication for a PPI was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), including the presence of gastroesophageal reflux disease and/or peptic ulcers and the prevention of non-steroidal anti-inflammatory drug-induced ulcers.
Statistical analysis
As for the statistical analyses, continuous variables are presented as the means ± standard deviations (SD) for variables with a normal distribution, or medians for those without. Comparisons between the patients with and without SBP were performed using Student's t-test for normally distributed variables or the Mann-Whitney U-test for nonnormally distributed variables. Dichotomous variables were compared using the chi-square test. All tests were two-tailed and conducted at a 5% level of significance. A logistic regression model was used for the multivariate analyses to identify risk factors for developing SBP. Continuous variables (age, creatinine, platelets, albumin and total bilirubin) that were not normally distributed were categorized for the multivariate analyses using the median of all patients (age, 68 years; creatinine, 1.11 mg/dL; platelets, 10.1×10 3 /mL; albumin, 2.6 g/dL; total bilirubin, 1.89 mg/dL; prothrombin time (PT)-international normalized ratio (INR), 1.30). The cumulative survival rate of the enrolled patients was calculated using the Kaplan-Meier method, and differences between the patients with and without SBP were analyzed using the log-rank test. All statistical analyses in the current study were performed using the IBM SPSS Statistics version 19 software program (IBM Japan, Tokyo, Japan). The study protocol was approved by the ethics board committee of the Teikyo University School of Medicine (#11-121).
Results
Demographic characteristics
Eighteen cirrhotic patients with SBP and 47 cirrhotic patients without SBP were admitted to our hospital due to the accumulation of ascites during the study period. All episodes of SBP were community acquired; no cases of nosocomial SBP were included.
The demographic characteristics of the patients enrolled in the current study are presented in Table 1 . The mean age was 65.6 years among the patients with SBP and 66.6 years among the patients without SBP, and the demographics of the patients were similar between those with and without SBP. Fifteen of the 18 patients with SBP (83%) and 26 of the 35 patients without SBP (74%) were given diuretics prior to admission. H2 receptor antagonists were administered in none of the patients with SBP and five of the patients without SBP within one month prior to admission (p= 0.15). No recent episodes of bacterial infection were noted in the patients with SBP, while three patients in the control group experienced urinary tract infections, all of which were successfully treated with ceftriaxone. In addition to these episodes, antibiotics were given in four of the patients with SBP and four controls, all of whom received kanamycin to prevent hepatic encephalopathy. There were significant differences in several laboratory tests between the two groups: both the serum bilirubin levels and INR values were significantly elevated in the patients with SBP (p=0.007 and p= 0.002, respectively). In addition, the platelet counts tended to be lower in the patients with SBP, although the difference was not significant (p=0.089), indicating the presence of more advanced liver disease in the patients with SBP. In accordance with these findings, the frequency of hepatic encephalopathy and hepatocellular carcinoma in the past or on admission was marginally increased in the patients with SBP compared to that observed in those without SBP (p=0.040 and 0.050, respectively). The mean MELD scores were 16.1 and 12.5 in those with and without SBP, respectively; thus, the scores were significantly higher in the SBP group (p= 0.009). The Child-Pugh classification also indicated the presence of more advanced liver disease in the patients with SBP. The number of patients with a Child-Pugh status of B/ C was 2/16 and 22/25 among those with and without SBP, respectively (p=0.007). Bacterial cultures of the ascitic fluid were performed before the commencement of antibiotic therapy in 10 and 39 patients with and without SBP, respectively. No definitive organisms were identified in the 10 patients with SBP, while Gram-positive and -negative bacteria were detected in three and one case, respectively, among the 39 patients without SBP.
PPI use and SBP
PPIs were used in 16 of 18 patients with SBP and 27 of 47 patients without SBP, exhibiting a significantly greater Table 2 ). The documented indications for PPI use in both groups are presented in Table 3 . PPI use was considered appropriate in four (22%) and five (11%) patients with and without SBP, respectively. In contrast, the indications for PPI use were deemed inappropriate in 13 (72%) and 18 (38%) and not clearly noted in one (6%) and 24 (51%) patients with and without SBP, respectively.
Prognosis of the patients with and without SBP
The cumulative survival curves of the patients with and without SBP are shown in Figure. As demonstrated, although not significant, there was a trend toward a poor prognosis in the patients with SBP (p=0.064). The threeyear survival rates were 12.5% and 21.9% among the patients with and without SBP, respectively. The multivariate analysis demonstrated that the only independent risk factor for survival was the MELD score, while neither the presence of SBP nor the use of PPIs significantly contributed to survival (data not shown).
Discussion
In this study, we examined whether PPI use contributes to the development of SBP in cirrhotic patients in the Japanese clinical setting. In Table 4 , we summarized previous reports investigating the association between the use of PPIs and the incidence of SBP in patients with cirrhosis. Accumulating evidence indicates that the administration of PPIs is an independent risk factor for the development of SBP in patients with liver cirrhosis (7-10), and, very recently, a large-scale retrospective cohort study from Korea reported a significant association between the administration of PPIs and the development of SBP (10) . However, some studies have failed to find any such associations in multivariate analyses (13) (14) (15) . In addition, most previous studies were performed in the US or Europe, where PPIs are sold as overthe-counter drugs without a physician's prescription. In contrast, PPIs are available only by prescription with a distinct indication and duration of treatment in Japan; thus, access to PPIs is strictly regulated and limited by the national health insurance coverage system. For instance, the administration of lansoprazole is officially limited to only eight and six weeks in patients with gastric and duodenal ulcers, respectively. Therefore, we assume the role of PPIs in the development of SBP may differ in Japan compared to that observed in other countries where PPIs are easily accessible. The present results, however, indicated that the use of PPIs is also an independent risk factor for the development of SBP in cirrhotic patients in Japan.
The current study has several limitations, primarily due to the study design. First, this study was performed as a singlecenter study, and we enrolled a relatively small number of patients (18 patients with SBP and 47 patients without SBP). The small number of patients may have weakened the statistical power to identify associations between the incidence of SBP and potential risk factors; therefore, we may have failed to detect clinical parameters contributing to the development of SBP. However, even if this is the case, PPI use was indeed detected to be an independent risk factor in the multivariate analysis, indicating a positive association between the administration of PPIs and the development of SBP. Second, this study included a retrospective design, similar to most previous studies; therefore, we cannot avoid several biases. It is possible that PPIs were administered in patients with epigastric pain, not caused by gastric acid, but rather simply due to massive ascites. Similarly, PPIs may have been given to patients with dyspepsia caused by impaired intestinal motility. Both massive ascites and impaired intestinal motility are predisposing factors for the development of SBP (1) . In this regard, a prospective study is needed to clarify the association between the incidence of SBP and the administration of PPIs. Nevertheless, this study clearly addressed the potential risk of PPI use with respect to the development of SBP in cirrhotic patients. A previous meta-analysis demonstrated that the risk for developing SBP is greater in patients treated with PPI therapy than in those treated with H2RA therapy (11), presumably due to the strong acid suppressive effects of PPIs. Indeed, bacterial overgrowth in the intestine and delayed gastric emptying are more common in patients who receive PPI treatment than in those who receive H2RA treatment (16, 17) . In addition, a longer duration of PPI therapy may increase the risk of SBP, although most of the patients in this study received PPIs for more than 90 days, and we cannot assess the relationship between the duration of PPI therapy and the risk of SBP. In this regard, PPIs should be given to cirrhotic patients for a definitive duration and discontinued promptly if possible.
In the current study, we also examined whether the administration of PPIs was appropriate according to the indications for PPI use approved by the PMDA. The approved indications for PPI use are limited to gastroesophageal reflux disease, peptic ulcers and the prevention of non-steroidal anti-inflammatory drug-induced ulcers in the clinical setting in Japan. Surprisingly, PPI use was clearly specified in the charts and appeared to be appropriate in only 22% and 11% of cases of patients with and without SBP, respectively. Inappropriate PPI use was observed in 72% and 38% of patients with and without SBP, while the indications for PPI use were not specified in 6% and 51% of cases, respectively. The administration of PPIs without a clear indication in patients with cirrhosis observed in our cohort has also been reported in other previous studies, suggesting an association between the use of PPIs and the incidence of SBP. For instance, Goel et al. reported that no documented indications for PPI use were found in 68% of patients with cirrhosis (9). Choi et al. also indicated that clear indications for PPI use were limited in 18% of patients with SBP and 6% of patients without SBP (8) . These findings suggest that the use of PPIs without a clear indication in patients with cirrhosis may result in the development of SBP.
In conclusion, we demonstrated in this retrospective study that the use of PPIs in cirrhotic patients with ascites is independently associated with the incidence of SBP in the Japanese clinical setting. As demonstrated in this study, the development of SBP was related to a poor prognosis among cirrhotic patients, although the difference was not statistically significant. Furthermore, the administration of PPIs has recently been suggested to be associated with several comorbidities (18) , including Clostridium difficile infection (19, 20) , osteoporosis and bone fractures (21) . It is obvious that treatment with PPIs is relatively safe and strongly indicated for the prevention of gastrointestinal bleeding in some patients; however, clinicians should be aware that the use of PPIs, especially long-term without a distinct indication, is potentially harmful.
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